Refine by
Bioprinting Technology Articles & Analysis: Older
17 news found
In her three years, CELLINK successfully launched multiple bioprinting systems, resulting in an expanded light-based portfolio and solutions targeting the pharmaceutical industry. Under her leadership CELLINK continued to be a driving force in fostering collaboration in the bioprinting space by opening Centres of Excellence at leading institutions in the USA, ...
ByCELLINK
CELLINK, a global leader in bioprinting technologies, is proud to announce a pioneering innovation in the field of regenerative medicine and tissue engineering with the launch of CELLINK Vivoink, the first-ever medical-grade bioink specially designed to support researchers on their clinical translational journey. ...
ByCELLINK
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting ...
ByCELLINK
Carcinotech has established itself as a leader in producing 3D bioprinted Micro-Tumors as well as 3D models based on cancer cell lines, incorporating CELLINK’s technology for automated workflows that have been perfected over the last 3 years. ...
ByCELLINK
Adding Allegro 3D to the portfolio enables BICO Bioprinting to strengthen its position as the global leader in providing 3D bioprinters. BICO has a robust portfolio of bioprinters, utilizing extrusion based, 2PP and DLP technologies. BICO has acquired all the shares in San Diego-based Allegro 3D Inc. ...
"The EXIS platform provides an unparalleled ability to recreate lymph node organoids in vitro. This powerful technology enables investigation of human B- and T-cell responses for a variety of applications, including antibody discovery and therapeutic immunogenicity,” said Melanie P. ...
Vancouver, BC, Canada - November 30, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce a research agreement with the University Health Network (UHN). Through this collaboration, Aspect Biosystems will combine its bioprinting technology with ...
Therefore, no bioprinted biological tissue has yet been implanted in a patient. The NGB bioprinting platform, which was developed by Poietis and recently installed in the LCTC of the AP-HM, meets these challenges thanks to numerous technological advances. ...
ByPoietis
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary ...
“This is such an exciting time for BIOLIFE4D, and I’m thrilled to accept the challenge of leading the Company into its first growth stage, toward commercialization of our pioneering 3D bioprinting technologies,” said Lewis. “From treatments like valve replacement and cardiac patches, to full-on heart transplants, to clinical research and ...
May will prove invaluable to Poietis leadership team, and we look forward to his insights and guidance to accelerate the advancement of our bioprinting platform technology to address the key challenges in tissue manufacturing and regenerative medicine”. “3D bioprinting is a once-in-a-generation ...
ByPoietis
Poietis is a biotechnology company specialized in the development and manufacturing of human tissues by bioprinting. Its main mission is to develop new therapeutic solutions based on its expertise in bioprinting technologies and in particular high-resolution laser assisted bioprinting. ...
ByPoietis
Further, it has developed a novel and unique bioprinting algorithm, consisting of printing parameters optimized for the whole heart. Coupling its proprietary bioink with patient-derived cardiomyocytes and its enabling bioprinting technology, BIOLIFE4D is able to bioprint a heart that, while smaller in size, replicates many of the ...
Poietis, 4D Bioprinting company, announces the issuance by the European Patent Office of a third patent covering its bioprinting technology: Patent No. ...
ByPoietis
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced the appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to its Board of Directors. ...
Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues. ...
ByPoietis
We envision combining Prometheus’ cell-based technologies together with the Poietis’Bioprinting technology to treat these defects effectively”, stated Prof. Frank Luyten, Chairman of the Division of Rheumatology at the University Hospitals Leuven and Director of Prometheus, the Skeletal Engineering Division at the KU Leuven in ...
ByPoietis